BofA Slashes Hims & Hers Q4 Forecast 6.5% Below Street
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.

Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
Galaxy Digital lands $460M strategic investment from leading asset manager to expand Helios data center campus in Texas and strengthen balance sheet.
The exclusive distributor for Corcept's drug Korlym quit after the company added a new pharmacy. This minor setback delays plans, but analysts advise buying the stock.